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A major challenge for cancer pathologists is to determine whether
a new tumor in a patient with cancer is a metastasis or an indepen-
dent occurrence of the disease. In recent years numerous studies have
evaluated pairs of tumor specimens to examine the similarity of the
somatic characteristics of the tumors and to test for clonal related-
ness. As the landscape of mutation testing has evolved, a number
of statistical methods for determining clonality have developed, no-
tably for comparing losses of heterozygosity at candidate markers,
and for comparing copy number profiles. Increasingly tumors are be-
ing evaluated for point mutations in panels of candidate genes using
gene sequencing technologies. Comparison of the mutational profiles
of pairs of tumors presents unusual methodological challenges: muta-
tions at some loci are much more common than others; knowledge of
the marginal mutation probabilities is scanty for most loci at which
mutations might occur; the sample space of potential mutational pro-
files is vast. We examine this problem and propose a test for clonal re-
latedness of a pair of tumors from a single patient. Using simulations,
its properties are shown to be promising. The method is illustrated
using several examples from the literature.
1. Introduction. One of the major routine tasks of cancer pathologists
is to determine if a new tumor identified in a patient with cancer is a metas-
tasis of the original primary tumor or a completely new, independent oc-
currence of the disease. Traditionally this diagnosis has been accomplished
by comparing the gross histologic features of the tumor cells, but in recent
years evidence from genetic markers has increasingly come to inform this
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decision. At the molecular level the DNA of individual tumors is character-
ized by many somatic changes, including mutations in individual genes and
losses or gains of large segments of DNA (copy number changes). Two tu-
mors that originally evolved from the same “clone” of cancer cells will thus
possess some somatic changes that are identical. These identical changes
will be present in both the primary tumor and the metastasis that is seeded
by the primary. In contrast, any similarities in mutational or copy number
profiles of pairs of independently occurring cancers must occur by chance.
Consequently, comparison of the DNA profiles for the extent of similarities
in the patterns of somatic changes is a powerful strategy for determining
the diagnosis of a new tumor as independent or as a clone of the original
primary.
Clonality testing of this nature has been studied by numerous investi-
gators over the past two decades. However, this period has been marked
by rapid changes in genetic technology, and so the kinds of data available
have evolved. Early studies typically involved examination of a few candi-
date markers for loss of heterozygosity (LOH), representing copy number
changes in the genetic region of the marker locus [Imyanitov et al. (2002),
Sieben et al. (2003), Dacic et al. (2005), Geurts et al. (2005), Orlow et al.
(2009)]. The LOH profiles would then be compared to determine if the two
tumors shared a clonal origin. Our group developed statistical tests designed
for this comparison and applied these in studies of melanoma and breast can-
cer [Begg, Eng and Hummer (2007), Ostrovnaya, Seshan and Begg (2008)].
However, as the technology evolved, investigators were increasingly drawn to
the use of genome-wide techniques for this purpose [Bollet et al. (2008), Gi-
rard et al. (2009)]. We have also examined in detail this framework and have
developed methods for comparing the genome-wide copy number profiles for
the purpose of clonality testing [Ostrovnaya et al. (2010), Ostrovnaya et al.
(2011)]. The statistical framework for formulating the comparison of copy
number profiles is radically different from the comparison of profiles of in-
dividual markers of LOH even though the fundamental goal of testing for
clonal origin is exactly the same. The current era is marked by a further
significant change in technology, the introduction of deep genetic sequenc-
ing [De Mattos-Arruda et al. (2014)]. This approach identifies individual
somatic mutations within genes such as single nucleotide variants, deletions,
insertions and other extremely localized events. These mutations are usually
identified by comparing the tumor sample with a matched normal sample
to screen out germ-line variants. Addressing the problem of clonality test-
ing from sequence data is very distinct from the challenges presented in our
earlier work on LOH and copy number profiles. In the former setting [Begg,
Eng and Hummer (2007), Ostrovnaya, Seshan and Begg (2008)] we dealt
with data on a limited number of markers where the marginal probabili-
ties of allelic losses could reasonably be considered to be constant, greatly
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simplifying the construction of the test. Our work on copy number profiles
was challenged by the problems of determining the locations of the allelic
changes and then formulating a probabilistic strategy for determining if
the locations of the changes could reasonably be considered to be identi-
cal [Ostrovnaya et al. (2010, 2011)]. With deep sequencing data, the major
challenges are different (and imprecisely known) marginal probabilities of
mutations at individual loci and the fact that the sample space of potential
mutations is vast and can be defined only loosely.
Information on point mutations has gradually become more common in
the clinic in recent years as specific driver genes have been identified, some
of which have important therapeutic implications in that mutations in these
genes may be targets for available drugs that have efficacy against tumors
with these mutations. For example, mutations in the gene EGFR can be tar-
geted by the drug erlotinib, while vemurafenib is especially effective against
tumors with mutations in the gene BRAF [Ko¨hler and Schuler (2013), Jang
and Atkins (2014)]. Consequently, such mutational data are likely to become
increasingly available routinely to pathologists when diagnosing a new tumor
in a patient with an existing tumor. It is our impression that pathologists
will typically conclude that the tumors are clonal if they match on a single
mutation of this nature. One of the goals we seek to address in this article
is to answer the question: is this conclusion justified? More generally, we
develop a framework for assessing the evidence for clonal relatedness of two
tumors when there may be one or more mutations observed in each tumor,
some matching and some nonmatching.
2. Motivating example and methods. We introduce the problem in the
context of an interesting recent example published by Kunze et al. (2014).
The data, displayed in Table 1, came from a patient with two primary colon
cancers, denoted T1 and T3, and tumors in both the right and left lungs.
Areas of the left lung tumor with distinct histological features were exam-
ined separately. The investigators were interested in whether or not the lung
tumors could be metastases of one or other of the colon primaries. Since mu-
tations in the gene KRAS are common in colon tumors the investigators per-
formed KRAS mutation testing. They discovered distinct KRAS mutations
in the left and right lung specimens, suggesting these tumors are indepen-
dent, but noticed that the left lung tumor shared a KRAS G12D mutation
with one of the colon primaries, suggesting that the left lung tumor might
be a metastasis of the T3 colon primary. We know from much previous ex-
perience that KRAS G12D mutations occur in about 8% of colon cancers.
Based on this fact, how strong is the evidence for a clonal link between these
two tumors? Clearly a match is evidence in favor of clonal relatedness, but
KRAS G12D is a common mutation and so it is not unlikely that two tumors
might share this mutation simply by chance. A match at a location that is
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Table 1
Data From Kunze et al. (2014)
Observed mutations
Colon tumors Lung tumors
Mutation Probability1 T1 T3 Right Left/Tubular Left/Mucinous
KRAS G12D 0.081 X X X
KRAS G12S 0.019 X
XPA G74V 0.004 X
PIK3CA Q546P 0.004 X
FBXW7 R465C 0.004 X
APC R283∗ 0.004 X
APC R499∗ 0.004 X
APC Q1065∗ 0.004 X
TP53 R158H 0.004 X
BRAF G596V 0.004 X
BAI3 V499L 0.004 X
PIC3C2B S314F 0.004 X
ETS1 K200N 0.004 X
IKZF1 M301I 0.004 X X
PRKDC R364H 0.004 X X
ZNF521 L1136V 0.004 X X
ALK E405∗ 0.004 X X
GUCY1A2 V627A 0.004 X
ACVR2A A62G 0.004 X
1Mutations that were not observed in TCGA were assigned a marginal probability of
(a+1)−1, where a is the number of cases observed in TCGA.
more uncommon would provide stronger evidence for clonality. To enhance
the evidence the investigators elected to perform additional targeted next
generation sequencing on a much more extensive panel of genes, and the re-
maining mutations detected are also displayed in Table 1. Here we see that
the colon T3 primary has five additional mutations detected while the left
lung tumor has 4 or 6 additional mutations depending on the histological re-
gion examined. However none of these additional mutations match the new
mutations in the colon primary. Clearly, the presence of new nonmatching
mutations diminishes the evidence favoring a clonal relationship, but how
do we quantify the negative evidence in these nonmatches with the positive
evidence in the KRAS G12D match?
2.1. Assumptions and notation. The key technical features of the prob-
lem are as follows. First, mutations could occur at a very large number of
genetic loci, depending on the size of the sequencing panel used. We denote
this number by n. We denote by m the number of loci at which mutations
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are actually observed in either tumor in the case under consideration. The
marginal mutation probabilities at each locus, defined as pi for the probabil-
ity of a mutation at the ith locus, will generally only be known approximately
for the common hotspot mutations that have been frequently observed in the
past, and must be small for mutations that have either never been observed
or not previously observed prior to occurrence in the case under considera-
tion. Since a match at a rare mutation is much less likely to occur by chance
the observance of such a match provides greater evidence for a clonal origin
for the tumors than a match at a common locus, so our testing procedure
must recognize this. We have elected to use data from the National Cancer
Institute-sponsored Cancer Genome Atlas (TCGA) to estimate these prob-
abilities in our examples [Kandoth et al. (2013)]. Specifically, we aggregated
frequencies observed in the TCGA database with data from the study in
question to obtain an estimate. New solitary mutations that were not ob-
served in TCGA were assigned a marginal probability of (a+ b)−1 where a
is the number of TCGA cases from the cancer site under investigation and
b is the number of cases in the study. In our testing procedure we assume
that these marginal mutation probabilities are known exactly. Later we in-
vestigate the consequences of inaccuracies in these estimates. An additional
key assumption in the statistical test in Section 2.2 below is independence
of mutations in different markers. This is not true for genes that are linked
by some known genetic pathways [Sweeney et al. (2009)] and we also explore
the implications of this simplifying assumption later in Section 3.3.
Finally, we assume that matching clonal mutations occur in the original
clonal cell, but that at some point a cell from this clone travels to another
site in the body and seeds the development of the metastasis. After this,
the two tumors can continue to evolve independently through further mu-
tation and the development of new dominant clones that contain both the
original set of mutations and additional independent mutations. Thus clonal
tumor pairs will possess identical mutations that occurred during the initial
“clonal” phase of development and additional sets of distinct mutations in
each tumor, most of which will be nonmatching but some of which could
be identical by chance. To model this process we use a parameter, ξ, that
characterizes the probability that a mutation will occur in the clonal phase
as opposed to the independent phase. Thus ξ = 0 for independent tumor
pairs and ξ > 0 represents the strength of the clonality signal. Clearly this is
likely to vary from case to case. If ξ is large then clonal tumors will typically
have very similar profiles, while if ξ is small then independently occurring
mutations will predominate.
2.2. A test for clonal relatedness. Let n be the total number of distinct
mutations (markers) that potentially could occur. Let A denote the set of
markers at which a matching mutation occurs on both tumors, let B denote
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the set of markers at which a mutation occurs on one tumor but not the
other, and let C denote the set of markers at which no mutations are ob-
served. Further let D denote the set of all loci, that is, D=A∪B∪C, and let
E denote the set of markers that experience mutations, that is, E =A∪B.
Applying the Neyman–Pearson lemma the most powerful test statistic for
distinguishing clonal versus independent tumor pairs is of the form
Su =
∑
i∈A
log
[
ξˆ
1− ξˆ
p−1i + 1
]
−
∑
i∈E
log
[
ξˆ
1− ξˆ
(1− pi)
−1 +1
]
+
∑
i∈D
log
[
ξˆ
1− ξˆ
(1− pi)
−1 +1− ξˆ
]
.
The last term is summed over all markers. Hence is a constant, and the
test reduces to weighted contributions from sets A and B, the markers at
which mutations are actually observed.
For the generalized likelihood ratio test we use the maximum likelihood
estimate of ξ in the test statistic. However, construction of a null reference
distribution presents a major challenge. This depends on the distribution of
the statistic generated from the full set of n markers. In practice markers
with mutations will represent only a tiny fraction of n, which itself may
be an extraordinarily large number. Consequently it is very appealing to
approach the problem by using a conditional test, conditioned on the set of
markers with mutations observed in one or both tumors, that is, i ∈ E. In
this conditional setting the likelihood ratio can be expressed as:
Sc =
∑
i∈A
log
[
ξˆ
1− ξˆ
p−1i +1
]
−
∑
i∈E
log
[
ξˆ
1− ξˆ
(2− pi)
−1 + 1
]
.(1)
The last term is a constant since it is summed over all of the mark-
ers in the reference set for the conditional test. Consequently the condi-
tional likelihood ratio test statistic depends solely on the weighted contri-
butions of the markers with matched mutations on both tumors, weighted
by log[(ξˆp−11 /(1− ξˆ))+ 1], the same weights used for the matches in the un-
conditional test. The maximum likelihood estimate of ξ in the conditional
setting can be obtained by maximizing the likelihood numerically under
the constraint that 0≤ ξˆ ≤ 1, where, by definition, ξˆ = 0 if no matches are
observed and ξˆ = 1 if all observed mutations are matched on both tumors.
The crucial practical advantage of the conditional test is that we can
generate relatively easily a null reference distribution since the sampling
depends solely on the markers with mutations observed in one or other
of the patient’s tumors. This number is relatively small in our examples,
but it is likely to be manageable, at most in the hundreds, even if full
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genome sequencing is used, based on projections from the TCGA project. To
obtain a reference distribution we generate the distribution of Sc under the
assumptions that matches occur randomly through independent sampling
and that at least one mutation is observed at each marker in the set E.
Specifically, let qi be the probability that there is a matching mutation at
the ith marker given that the marker is mutated in at least one of the two
tumors. Then under the null hypothesis that the tumors are independent
qi = p
2
i /(p
2
i +2pi(1− pi)).
To simulate the null distribution of Sc we randomly generate the matches
over the set E, that is, for the ith marker of the jth of T simulations we
generate xij as a Bernoulli random variable with probability qi where xij =
1 if there is a match and 0 otherwise Then the test statistic for the jth
simulation is given by
Sj =
∑
i∈E
[
xij
{
log
(
ξ˜j
1− ξ˜j
p−1i +1
)}
−
{
log
[
ξ˜j
1− ξ˜j
(2− pi)
−1 + 1
]}]
for j = 1, . . . , T,
where ξj is the MLE based on data from the jth simulation. The p-value
is given by
∑T
j=1 I(Sj > Sc)/T . The critical value of this test at the one-
sided α level, denoted kα is the smallest value of kα such that
∑T
j=1 I(Sj >
kα)/T < α.
3. Statistical properties. In the following we use simulations to address
several questions about the preceding testing strategy. First, since the actual
mutational profiles of tumors arise through a random process represented by
unconditional sampling, is the conditional test valid? Further, in discarding
information about the markers that were tested but exhibited no mutations
in either tumor are we materially reducing the efficiency of the test? Sec-
ond, given that in practice we must use estimates of the marginal mutation
probabilities of the mutations that are observed in any tumor pair under
consideration, how sensitive is the test to inaccuracies in these marginal
probabilities? Third, to what extent are the properties of the test affected
by correlations among mutations?
3.1. Validity and efficiency of conditioning on observed mutations. Be-
cause of the computational barriers to use the unconditional test when there
are large numbers of markers that could harbor a mutation, allied to the fact
that the unconditional test represents the gold standard against which to
compare the conditional test, we have constructed simulations in configu-
rations where the number of mutations observed reflect settings that we
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Table 2
Validity and efficiency of conditional test
Mean #
mutations
per tumor
Clonality
signal
Mean #
matching
mutations
Frequency of p < 0.051
Unconditional
test (calibrated) Conditional test
Conditional test
(calibrated)
5 0.0 0.10 0.05 0.01 0.05
5 0.1 0.56 0.41 0.36 0.40
5 0.25 1.32 0.72 0.65 0.70
10 0.0 0.21 0.05 0.02 0.05
10 0.1 1.17 0.60 0.57 0.59
10 0.25 2.60 0.92 0.89 0.90
20 0.0 0.45 0.04 0.03 0.05
20 0.1 2.41 0.83 0.81 0.82
20 0.25 5.28 0.99 0.99 0.99
1Each row of the table involved a simulation with 10,000 markers in which the reference
distribution for the test involved sampling from the null distribution 5000 times, and in
which the test was repeated 1000 times to estimate the size (when the clonality signal is 0)
or power (when the clonality signal is >0). The marginal frequencies were constructed in
the following way: For configurations with five mutations per tumor, 10 of the loci had a
marginal probability of 0.10 and the remaining 9990 had a marginal probability of 0.0004.
For configurations with 10 mutations per tumor, 20 of the loci had a marginal probability
of 0.10 and the remaining 9980 had a marginal probability of 0.0008. For configurations
with 20 mutations per tumor, 20 of the loci had a marginal probability of 0.10 and the
remaining 9960 had a marginal probability of 0.00016.
believe will be realistic, but where the total number of markers is chosen to
be small enough to facilitate the comprehensive computation required in the
unconditional setting. Thus we construct simulations in which n= 10,000.
We calculate the size and power of the test for various combinations of the
clonality signal, ξ, the number of markers with mutations observed in either
or both tumors (m) and their associated marginal probabilities {pi}.
In Table 2 we present the test characteristics in the setting in which the
assumptions are correct, that is, the mutations are generated independently
and the marginal mutation probabilities used in the test are accurate. The
configurations of marginal probabilities reflect in general terms the nature
of somatic mutation, namely, a few “common” markers with marginal prob-
abilities of 0.1, and a large number of “rare” markers. We generated config-
urations in which the mean numbers of mutations observed per tumor are
five, 10 and 20, with clonality signals of 0 (null), 0.1 and 0.25. Details of
the actual marginal probabilities are provided in the table footnotes. The
results show that the conditional test is valid. This can be seen in the col-
umn “Conditional Test” for null (ξ = 0) settings, that is, the size of the
test is consistently less than the nominal 5% level of the test, regardless of
the configuration of marginal probabilities. To compare the power of the
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conditional and unconditional tests we “calibrated” the results by random-
ization to ensure that the test size is always exactly 0.05. The results show
that the conditional test has slightly lower power than the unconditional
test, but that the bulk of the information appears to be captured by the
conditioning.
3.2. Inaccuracies in marginal probability estimates. Our test depends on
specification of the marginal mutation probabilities for each locus at which
a mutation is observed. At this stage of genomic knowledge we do not have
accurate information for ths purpose so our strategy is necessarily ad hoc.
We have addressed the likely consequences of misspecification from two per-
spectives. First, we generated simulations in which we added noise to the
marginal probabilities used in the data analyses. This was accomplished
by perturbing the “true” marginal probabilities {pi}, that is, those used to
generate the data, to {p∗i }, using log{p
∗
i /(1 − p
∗
i )} = log{pi/(1 − pi)} + εi,
where εi is a random N(0,0.5) error term. These incorrect frequencies were
used both for calculating the test statistic and for generating the reference
distribution. These errors correspond approximately to the statistical uncer-
tainty in mutation probability estimates obtained for marginal probabilities
of “common” markers in the range 0.05–0.10 from sample sizes in the range
of 500–1000, roughly the current state of knowledge based on data from
The Cancer Genome Atlas project [Kandoth et al. (2013)]. The results are
in the column “Random Errors” in Table 3 and these can be contrasted with
the results based on the true probabilities in the preceding column. The re-
sults demonstrate a very modest anti-conservative trend. A possibly greater
concern is the fact that for the vast majority of potential mutational loca-
tions in the genome no previous mutation has been observed. Consequently
each time a first occurrence is observed we have elected in practice to use
a marginal estimator, N−1, where N is the total number of patients exam-
ined to date, including those from publicly available databases like TCGA.
It is highly probable that this will typically be an overestimate because of
the large number of potential mutations in the genome and the fact that
most of the mutations observed to date have only been seen in a single pa-
tient. To address the impact of this, we constructed simulations in which the
marginal probabilities of all of the “rare” mutations used in the test were
overestimated by an order of magnitude compared to the probabilities used
in generating the data. These are displayed in the column headed “Rare Mu-
tation Overestimation” in Table 3. This phenomenon makes the test more
conservative since overestimation of the marginal probability reduces the
strength of evidence favoring clonality, but clearly does not threaten test
validity. However, substantial power is still apparent for the kinds of config-
urations examined.
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Table 3
Sensitivity of the test to inaccuracies in the marginal mutation probabilities
Frequency of < 0.05
Test calculated using
Mean #
mutations
per tumor1
Clonality
signal
Mean #
matching
mutations
True
probabilities2
Random
errors3
Rare mutation
overestimation4
5 0.0 0.10 0.01 0.02 0.01
5 0.1 0.56 0.36 0.37 0.33
5 0.25 1.32 0.65 0.67 0.65
10 0.0 0.21 0.02 0.04 0.00
10 0.1 1.17 0.57 0.58 0.37
10 0.25 2.60 0.89 0.90 0.80
20 0.0 0.45 0.03 0.06 0.00
20 0.1 2.41 0.81 0.82 0.54
20 0.25 5.28 0.99 0.99 0.94
1In all configurations the data are generated using the same set-ups as described in the
footnotes to Table 1 with regard to the marginal probabilities of the mutations and the
clonality signal.
2Here the test is computed by using the same marginal probabilities as were used in the
data generation.
3For the purposes of calculating the test statistic and its reference distribution, the
marginal probabilities of the markers {pi} were perturbed with random errors to {p
∗
i },
using log{p∗i /(1− p
∗
i )}= log{pi/(1− pi)}+ εi where εi is a random N(0,0.5) error term.
4For the purposes of calculating the test statistic and its reference distribution, the
marginal probabilities of the common markers are assumed to be correct but the proba-
bilities of the rare markers are overestimated by a factor of 10.
3.3. Impact of correlations between markers. We address the influence
of negative and positive correlation between markers separately. It is well
known that genes that operate in carcinogenic pathways will often not be
co-mutated in tumors. That is, a mutation in one gene in the pathway will
be sufficient to lead to the tumorigenic effects needed. An example is the mu-
tual exclusivity of BRAF and NRAS mutations in melanomas. As a result,
we know that strong negative correlations between mutations in different
genes can occur. To model this kind of phenomenon we generate data where
subsets of the markers are classified into groups of “pathways” such that
co-incident mutations within a pathway are not possible, that is, there is ex-
clusivity between mutations in each pathway. To accomplish this we simply
generated a single outcome from a multinomial comprising all the mark-
ers in the pathway with an additional cell of the multinomial representing
no mutation. Further details are in footnote 3 of Table 4 with results pre-
sented in the column “Negative Correlations.” These results show that this
phenomenon has little impact on either the size or the power of the test.
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Table 4
Sensitivity of the test to correlations in the markers
Frequency of < 0.051
Mean #
mutations
per tumor1
Clonality
signal
Mean #
matching
mutations Uncorrelated
2
Negative
correlations3
Positive
correlations4
0.3 0.9
5 0.0 0.10 0.01 0.04 0.02 0.02
5 0.1 0.56 0.34 0.41 0.31 0.24
5 0.25 1.32 0.64 0.66 0.62 0.46
10 0.0 0.21 0.02 0.02 0.02 0.03
10 0.1 1.17 0.57 0.55 0.56 0.40
10 0.25 2.60 0.87 0.87 0.84 0.67
20 0.0 0.45 0.04 0.02 0.04 0.05
20 0.1 2.41 0.81 0.83 0.75 0.55
20 0.25 5.28 0.98 0.99 0.98 0.87
1In all configurations, the 10,000 markers are generated using the same marginal probabil-
ity set-ups as described in the footnotes to Table 2 with regard to the marginal probabilities
of the mutations and the clonality signal.
2Here the test is computed by using the same marginal probabilities and (uncorrelated)
data generation as in Tables 2 and 3.
3In these configurations, negative correlation between “pathways” is generated as follows,
designed such that the overall mean numbers of matching mutations are equivalent to
the corresponding uncorrelated configuration. Common markers are generated in blocks
of 10 using a single draw from a multinomial distribution in each block with 10 mutually
exclusive outcomes and fixed marginal frequency of 0.1 each. One, two or four such multi-
nomials, respectively, are generated for each tumor under the three scenarios (mean #
mutations of five, 10 or 20). In addition, 5000 rare markers are generated in 50 blocks of
mutually exclusive markers of size 100 and fixed rare marginal frequencies for each muta-
tion (4/9990, 8/9980 and 16/9960, resp., for the three scenarios). That is, we generated one
draw from each multinomial with 101 potential outcomes where none of the 100 markers
exhibit a mutation when 101th outcome is selected (probability of the 101st outcome is
9490/9990, 9180/9980 and 8360/9960, resp., for the three scenarios). For markers that be-
long to these multinomial blocks, the clonality status is drawn once for a whole block, that
is, the whole blocks rather than individual mutations are considered clonal or independent.
The remaining 4990, 4980, or 4960 markers in the three scenarios are independent of each
other and of multinomial blocks and are generated as described above. The test statistic
and reference distribution are calculated assuming all markers are independent.
4Similar to (3) above, one, two or four blocks of size 10 of common markers and 50 blocks
of size 100 of rare markers are generated with positive correlation. To accomplish this we
generated multivariate normal variates Y of size 10 or 100 with 0 mean, variance 1 and
pairwise correlations of 0.3 or 0.9. The correlated binary mutation outcomes were deter-
mined by dichotomizing these normal variables at the appropriate marginal frequencies.
Clonality status was drawn on per-block basis as described in (3) above, and the remaining
markers were generated independently. Note that in this set-up it is possible for greater
than one mutation to be observed within a block (indeed this is increasingly likely as the
correlation increases) while in the mutually exclusive construct in (3) above at most one
mutation is observed in each block.
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From an intuitive standpoint, positive correlation is a much more prob-
lematic phenomenon in principle since it will lead to a greater chance of pairs
of matched loci occurring together, with the potential to greatly inflate the
evidence favoring clonality when the reference distribution assumes inde-
pendence of markers. To address this we generated data where once again
the markers were grouped into “pathways.” However, in contrast to the mu-
tually exclusive set-up above, here sets of markers with pairwise positive
correlations are generated within the pathways with the same marginal fre-
quencies as for the corresponding “uncorrelated” framework. Briefly, mark-
ers within groups are generated as multivariate normal correlated variables
which are then dichotomized to produce the desired marginal frequencies
(further details are provided in the footnotes to Table 4). When the within-
blocks correlation is a moderate 0.3 the impact on the test appears to be
a modest reduction in power, but the power decreases notably when the
correlations are high (0.9). The factors bearing upon this loss of power are
complex. The increased tendency for joint occurrence of clonal pairs of cor-
related markers has an anti-conservative influence on the test, but this is
offset by the diminished effective sample size due to the presence of correla-
tion. Further discussion of this issue is provided in a supplementary material
[Ostrovnaya, Seshan and Begg (2015)]. We believe that the scenarios used
in Table 4 that suggest the typical overall effect will be conservative provide
a persuasive picture of the likely impact in practice. To gauge this we ex-
amined the empirical correlations between common genes using the TCGA
data for the four major solid tumors: breast, colon, lung, prostate. That is,
we correlated genes rather than individual mutations: logically the latter
correlations should be lower. We only looked at common genes since for rare
mutations the vast preponderance of mutation pairs have never been ob-
served to occur together, making it difficult to determine reliably the likely
correlation structure. We cross-tabulated the occurrence of mutations in all
pairs of genes that occur with greater than 10% frequency and derived the
underlying distribution of pairwise correlations on the assumption that mu-
tations are binary classifications from latent correlated normal variates. The
75% percentile of the pairwise tetrachoric correlations, computed using the
“polychor” function from the R package “polychor,” is 0.19 for prostate, 0.32
for lung, 0.15 for breast and 0.50 for colorectal, while the maximum values
are 0.38 for prostate, 0.59 for lung, 0.35 for breast and 0.86 for colorectal.
That is, very high correlations will only occur occasionally and the prepon-
derance of the gene pairs have correlations that are sufficiently low to have
at worst very modest impact on the power of the test.
4. Examples. We illustrate the test using examples from the recent lit-
erature. Both studies involved mutational profiling addressing the clonality
TESTING FOR CLONAL RELATEDNESS 13
of primary metastasis pairs of tumor specimens, as described earlier in Sec-
tion 2. In the example from Kunze et al. (2014) the investigators performed
next generation sequencing on two colorectal tumors considered clinically
to be multifocal and two nonsmall cell lung cancers, one in the left and
one in the right lung, all identified synchronously in the same patient (Ta-
ble 1). Recall that initially the investigators had only information regarding
a matching mutation between the T3 colon tumor and the tumor in the
left lung at KRAS G12D. Our test based on this single locus has a p-value
of 0.042. Additional mutational testing identified five new mutations in the
T3 lesion and either four or six additional mutations in the mucinous and
tubular portions of the left lung lesion, respectively, though none of these
were matched in the colon versus lung comparisons. By accounting for these
additional nonmatches, our test leads to p-values of 0.063 and 0.067 when
comparing the colon T3 with the mucinous and tubular lung lesions, respec-
tively. This shows that nonmatches contribute small amounts of evidence
against clonality and that this negative evidence will accumulate as more
nonmatches are observed.
We have also analyzed another published example of a celebrated recent
study involving panel sequencing of nine distinct local foci of prostate cancer,
a lymph node metastasis and a series of distant metastases obtained from
autopsy specimens many years after the primaries were surgically removed
[Haffner et al. (2013)]. Mutations were identified in the PTEN, TP53, SPOP
and ATRX genes. The data in Table 5 show that the four metastases are
all clearly related through matches in at least three of these four genes
(p < 0.001 for tests of any pair of metastases). Six of the primary specimens
have no matches with the metastases. One primary, denoted P1, matches
with the metastases on the PTEN, TP53, and SPOP mutations (p < 0.001)
and the authors concluded that this tumor, the least advanced of the nine
primary specimens on a histopathologic basis, contains the lethal clone that
led to the metastases. However, two of the other primaries have matches
with the metastases on the mutation SPOP F133L, and so it is pertinent to
address the statistical evidence that these primaries may be clonally related
to each other and to the metastases. In fact, a comparison of either P6 or P8
with P1 is significant (p= 0.02), and a comparison of either P6 or P8 with
any of the metastases is also significant (p = 0.02). In short, the authors’
interpretation that the low grade P1 tumor is the sole primary tumor that
is related to the metastases may be an incomplete explanation of the clonal
evolution of these tumors. Interestingly, the local lymph node possesses none
of these mutations and it is entirely possible that it is linked clonally to some
of the other primary tumors through shared mutations in genes that were
not tested. More extensive mutation testing of additional genes would be
needed to fully resolve the clonal development of these tumors.
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Table 5
Data from Haffner et al. (2013)
Observed mutations
Site Tumor PTEN del. TP53 R248Q SPOP F133L ATRX inversion
Mutation probabilities → 0.004 0.008 0.023 0.004
Prostate P1 X X X
P2
P3
P4
P5
P6 X
P7
P8 X
P9
Local Node L1
Lung B1 X X X
Liver M5 X X X X
Gastric Node M38 X X X X
Lung M40 X X X X
Mutations that were not observed in TCGA were assigned a marginal probability of (a+
1)−1, where a is the number of cases observed in TCGA.
We note that in both these examples several tests were performed between
different tumor pairs from the same patient in order to explore the possible
relationships between individual tumor pairs. We have not performed any
multiple testing adjustments. We note that these tests are structurally de-
pendent, and indeed the deciphering of the full set of clonal relationships
among multiple tumors in a single case represents a more complex problem
that is beyond the scope of this article.
5. Discussion. Clonality testing using sequencing is likely to be an emerg-
ing clinical application. It has been known for at least two decades that more
accurate pathological diagnosis of metastases is possible using mutational
testing of tumor samples. However, as yet, routine mutational testing has
not entered the clinic. We are now entering an era in which routine clinical
testing of tumor samples is likely to become commonplace as oncologists
seek to identify actionable mutations for targeted therapy. In the medium-
term the technologies will involve deep sequencing of panels of genes likely
to harbor mutations of therapeutic potential, such as the one employed in
Wagle et al. (2012). A by-product of such testing will be the availability of
mutational data to test the clonal relatedness of metastases with their pu-
tative primaries. We have provided a testing strategy to perform such clas-
sifications, one that is conceptually and computationally straightforward to
apply, and which appears to enjoy good statistical properties.
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An unusual conceptual challenge in constructing a test in this context
if the fact that the sample space is ill-defined due to the fact that it is
not possible to specify precisely the number of potential ways in which a
DNA mutation can occur. Additionally, for most realistic gene panels, the
number of potential mutations is extremely large, making it computationally
challenging to establish a reference distribution for any test statistic. We
circumvented these problems by constructing a conditional test, conditional
on the actual set of mutations observed. We showed through simulation that
this conditional test is valid and captures most of the relevant information.
Our examples showed that strong evidence for clonal relatedness is pos-
sible even if matches are observed in only two genes. However, a match in
a single, recurring mutation in major cancer genes such as KRAS, BRAF,
PTEN, etc., may not provide sufficient evidence to demonstrate clonal relat-
edness convincingly. Stronger evidence is possible if the match occurs at a
more rarely occurring genetic locus. If clonality testing were to be performed
routinely in the clinic the gene panel should ideally be sufficiently large to
ensure that several mutations will be observed in all cases encountered.
A notable limitation to our approach is the fact that we must assign values
to the marginal probabilities at each locus. In our example we used empir-
ical relative frequencies as estimates for the marginal probabilities, derived
using the publicly available TCGA data. This raises the question of how to
update these marginal estimates, and in particular how to assign probabil-
ities for mutations seen for the first time in a new patient, something that
is likely to occur quite frequently. If one uses smaller marginal probability
estimates for nonrecurring mutations based on the recognition that there are
huge numbers of genetic loci at which mutations can potentially occur then
the p-values will be smaller. We advocate an estimation strategy that results
in the test being somewhat conservative, as shown in the simulations. Our
simulations of settings in which we substantially overestimated the marginal
probabilities demonstrated the degree of conservativeness to be expected if
these probabilities are overestimated by an order of magnitude. As evidence
gradually accrues about the frequency of specific mutational events in can-
cers, our uncertainty about the assignment of marginal probabilities will
decrease, notably for the more commonly occurring mutations. Our test is
also based on the assumption that mutational events occur independently at
different loci. While this clearly is not literally true across the genome, our
investigation of the impact of departures from independence showed that the
kinds of dependencies observed between mutations in the TCGA project are
likely to have modest impact on the properties of the test.
As a final cautionary note it must be recognized that all mutations from
sequencing panels are called after a complex laboratory and data normaliza-
tion process that can be influenced by numerous potential biases, including
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contamination of the specimen with normal cells and various laboratory pro-
cessing artifacts. Also, tumors are heterogeneous and some mutations may
only be present in a small subset of tumor cells and thus detectable only if
sequencing coverage is sufficiently high. These artifacts can introduce false
positives or false negatives. In short, reaching a definitive diagnosis of clonal
relatedness simply because one of many observed mutations is determined
to be matched in the two tumors may overstate the true strength of the
evidence, even if the matching locus is a “rare” locus. However, with proper
curation of the called mutations false positive matches due to germ-line ef-
fects or other artifacts are unlikely.
SUPPLEMENTARY MATERIAL
Supplementary appendix (DOI: 10.1214/15-AOAS836SUPP; .pdf). Ex-
planation of results of simulations with correlated markers. In the on-line
supplementary appendix we provide additional calculations and graphs that
provide an explanation of the power trends in the presence of correlated
markers..
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